Celgene has formed a strategic collaboration with Presage Biosciences, a spin-off from the Fred Hutchinson Cancer Research Center, to use the company’s three-dimensional in vivo drug analysis technology to identify novel drug combinations for the treatment of patients with solid tumours. The deal will help Celgene to enhance the efficiency of its early-stage R&D in oncology. Presage’s technology platform received its first validation when the company partnered with Millennium Pharmaceuticals, Takeda Pharmaceutical’s oncology division, in April 2012.